MLMaría Generosa Crespo Leiro

María Generosa Crespo Leiro

*This is an algorithmically generated author record based on publicly available information.

Recognitions

Top Cited Scholar (2024,2025,2026)

María Generosa Crespo Leiro has a total of 1000 co-authors. Here are the top co-authors by number of shared publications:

  • Juan Francisco Delgado

    Cardiology, Hospital Universitario 12 de Octubre, Instituto de Investigación Sanitaria Hospital 12 de Octubre (imas12), Centro de Investigación Biomédica en Red de Enfermedades Cardiovasculares (CIBERCV), 28041 Madrid, Spain

    51 shared publications
  • Aldo Pietro Maggioni

    Centro Studi ANMCO—Heart Care Foundation, 50121 Florence, Italy

    32 shared publications
  • Eduardo Barge-Caballero

    31 shared publications
  • Gerasimos Filippatos

    National and Kapodistrian University of Athens, School of Medicine, Athens, Greece, and University of Cyprus, School of Medicine, Shacolas Educational Centre for Clinical Medicine, Nicosia, Cyprus

    22 shared publications
  • Luis Almenar

    21 shared publications
  • Luis Almenar-Bonet

    Department of Cardiology, La Fe University Hospital, Valencia, Spain; Centro de Investigación Biomédica en Red de Enfermedades Cardiovasculares (CIBERCV), Madrid, Spain

    21 shared publications

Latest Publications

  • Open Access

    Mass Spectrometry-Based Amyloid Typing in FFPE Biopsies: A Five-Year Prospective Experience from a Tertiary Academic Center in Spain

    by Valentina Calamia, Patricia Fernández-Puente, Selva Riva-Mendoza, Patricia Quaranta, Beatriz Rocha, Lucía Lourido, Jorge Pombo-Otero, María Generosa Crespo-Leiro, Olalla Ramil-Gómez, Gonzalo Barge-Caballero, et al.

    Background: Accurate amyloid subtyping is essential for patient management but remains challenging with antibody-based methods. We prospectively evaluated a standardized LC-MS/MS workflow for routine amyloid typing, focusing on diagnostic yield, operational performance, and added value in cases not fully resolved by conventional methods. Methods: From 2020 to 2025, 115 FFPE biopsies from patients with suspected amyloidosis were analyzed at Hospital Universitario A Coruña, Spain, without laser microdissection. Proteins were identified and quantified using PEAKS, with a peak-area cutoff ≥10 5 for candidate fibril proteins. Results: Seventy-nine cases (69%) were amyloid-positive, 22 (19%) negative and 14 (12%) indeterminate. AL (51%), ATTR (32%) and AA (10%) predominated, with additional AH (5%), mixed ATTR+AL, hereditary ATTRv and AIns amyloidoses. Binary concordance with conventional techniques ranged from 85.7% to 91.5%. LC-MS/MS provided additional diagnostic information in 64/110 evaluable cases (58.2%), including additional subtyping information in 53/110 (48.2%). The workflow also enabled relative quantification of variant versus wild-type TTR peptides and characterization of SAA post-translational modifications. Mean turnaround time was approximately two weeks and MS findings informed clinical management. Conclusions: LC-MS/MS amyloid typing was clinically feasible in routine FFPE biopsies without laser microdissection and supported identification of common, rare and mixed amyloid types.

  • Management of Heart transplant recipients for the non Heart Transplant health care provider. A Clinical Consensus Statement of the Heart Failure Association (HFA) and the Association of Cardiovascular Nursing & Allied Professions (ACNAP) of the ESC

    by Guillaume Baudry, Emer Joyce, Marianna Adamo, Rafaela Batista dos Santos Pedrosa, Tuvia Ben Gal, Michael Bonios, Maria Generosa Crespo-Leiro, Ida E Hoejskov, Attilio Iacovoni, Chris Kapelios, et al.

    Heart transplantation (HTx) remains the gold standard treatment for selected patients with advanced heart failure and survival after transplantation has substantially improved over recent decades. As a consequence, the number of long-term HTx recipients continues to increase, and these patients are now frequently encountered in routine practice outside specialized transplant centers. Their management remains complex due to the use of chronic immunosuppression, transplant-specific complications, and a growing burden of comorbidities in the perspective of increasing longevity. Non-transplant cardiologists, general practitioners, and other healthcare professionals are therefore increasingly involved in their care but often have limited experience of post-transplant management. This clinical consensus statement from the Heart Failure Association (HFA) and the Association of Cardiovascular Nursing & Allied Professions (ACNAP) of the ESC provides practical support and a structured framework for healthcare providers involved in the care of HTx recipients outside dedicated transplant centers. The document reviews key aspects of post-transplant management, including outlining principles of care according to time from transplantation, essential knowledge around immunosuppressive therapy and drug monitoring, recognition and initial management of rejection, infection prophylaxis and treatment, and surveillance of long-term complications such as cardiac allograft vasculopathy, malignancy, chronic kidney disease, and metabolic disorders. In addition, specific clinical situations frequently encountered in practice—including fertility and pregnancy, non-cardiac surgery, rehabilitation, and palliative care—are discussed. Particular emphasis is placed on the organization of shared-care models between transplant centers and community providers and on identifying clinical scenarios requiring early referral. Through providing practical recommendations and a structured framework for follow-up, this document aims to support non-specialist clinicians in the safe management of HTx recipients and to facilitate timely collaboration with transplant centers.

  • Influence of donor-transmitted coronary artery disease on the progression of coronary vasculopathy after heart transplantation

    by David Couto-Mallón, Luis Almenar-Bonet, Eduardo Barge-Caballero, Francisco José Hernández-Pérez, Juan Delgado-Jiménez, María Jesús Valero-Masa, María Ángeles Castel-Lavilla, Sonia Mirabet-Pérez, Iris Paula Garrido-Bravo, Carles Díez-López, et al.

  • Short-Term Mechanical Circulatory Support Before Heart Transplantation and Early Outcomes: Insights From the International Primary Graft Dysfunction Consortium

    by Mercedes Rivas-Lasarte, Eduard Rodenas-Alesina, Yasbanoo Moayedi, Lauren K. Truby, Farid Foroutan, Erik Henricksen, Marisa Signorile, Nitish K. Dhingra, Laura Hastenteufel, Chun-Po S. Fan, et al.

  • Open Access

    “Frailty and cognitive impairment are associated with early adverse clinical events and angiographic differences in older adults with acute coronary syndrome”

    by Ana Isabel Molina-Ramos, Victoria Doncel-Abad, Ada Carmona-Segovia, Víctor Becerra-Muñoz, Luis García-Rodríguez, Miguel Romero-Cuevas, Jorge Segovia-Reyes, María Jiménez-Salva, María Robles-Mezcua, María Díaz-Ottaviano, et al.

    Aims: Geriatric vulnerabilities may compromise short-term prognosis in acute coronary syndrome (ACS); however, the prognostic value of geriatric assessment in older adults with ACS remains insufficiently explored. This study aimed to evaluate the association between selected geriatric assessment domains and 30-day early adverse clinical events and to explore whether frailty and cognitive impairment were associated with different angiographic patterns. Methods and results: In a prospective observational single-center study, 211 patients aged ≥70 years hospitalized with ACS underwent assessment of frailty (FRAIL scale), functional status (Barthel Index), cognition (Pfeiffer’s SPMSQ), and comorbidity burden (Charlson Comorbidity Index). Logistic regression analyses were performed, and angiographic parameters were recorded. In univariable analyses, higher FRAIL scores (OR = 1.59, 95%CI = 1.21–2.09, p = 0.001) and higher SPMSQ error counts (OR = 1.56, 95%CI = 1.15–2.10, p = 0.004) were associated with 30-day early adverse clinical events. In the clinically informed multivariable model including all geriatric domains, higher SPMSQ error counts remained associated with the outcome (OR = 1.46, 95%CI = 1.06–2.00, p = 0.020). In a secondary reduced exploratory model, FRAIL scores (OR = 1.52, 95%CI = 1.14–2.01, p = 0.004) and SPMSQ error counts (OR = 1.46, 95%CI = 1.07–1.98, p = 0.016) were retained, with modest discrimination (AUC=0.70, 95%CI = 0.61–0.79, p < 0.001). Coexisting frailty and cognitive impairment identified a subgroup at particularly high risk, with 72.7% experiencing events, and exploratory angiographic analyses showed associations with culprit lesion calcification (OR = 3.08, 95%CI = 1.16–8.15), diffuse culprit disease (OR = 3.08, 95%CI = 1.10–8.61), single-vessel disease (OR = 2.85, 95%CI = 1.11–7.35), and thrombus in non-culprit lesions (OR = 20.75, 95%CI = 1.69–254.76). Conclusions: In older adults with ACS, frailty and cognitive impairment were associated with 30-day early adverse clinical events and a different angiographic pattern in exploratory analyses. Incorporating brief nurse-administered geriatric assessment into routine ACS care may support risk stratification and multidisciplinary clinical decision-making.


  • Open Access

    Enterococcal Infections in Left Ventricular Assist Device Recipients: Two Clinical Cases and Systematic Review

    by Cristina Gay, Lucía Ramos-Merino, Elena Sandoval, David Couto-Mallón, Andrés Perissinotti, María García-Vieites, Eduardo Barge-Caballero, Marta Farrero, Marta Hernández-Meneses, María G. Crespo-Lerio

    Background: Infections remain a major complication in patients with left ventricular assist devices (LVADs). Enterococcal infections are increasingly recognized and are therapeutically challenging because of antimicrobial tolerance, biofilm formation on prosthetic material, and the frequent impossibility of device removal. Objective and method: We report two clinical cases of Enterococcus faecalis LVAD infection and a PRISMA-based systematic review of cases published between 1996 and 2025 that were identified through PubMed/MEDLINE. Primary outcomes were clinical cure, relapse or recurrence, mortality, and device removal. Results were synthesized descriptively. Results: Seventeen cases were analyzed, including 15 previously reported cases and two new cases. E. faecalis accounted for 47% of infections, Enterococcus faecium for 29%, and Enterococcus spp. without species identification for 24%. Bacteremia was the most common presentation, occurring in 76%, whereas LVAD-associated endocarditis occurred in 18%. Driveline or pocket involvement was reported in 41%. Suppressive antimicrobial therapy (SAT) was used in 29%, often as a bridge to heart transplantation. Cultures from explanted LVAD components were positive in 47% of cases despite prolonged antimicrobial therapy. Recurrence or relapse and overall mortality each occurred in 18% of patients. Conclusions: Enterococcal LVAD infections may be associated with microbiological persistence despite prolonged therapy. SAT may help control infection in selected patients and bridge to heart transplantation when device removal is not feasible.

  • Open Access

    Old donors for young heart transplant recipients: Clinical implications of an emerging phenomenon

    by Lidia Vilches-Miguel, Luis Almenar-Bonet, Maria G. Crespo-Leiro, Francisco J. Hernández-Pérez, Francisco González-Vílchez, Maria Dolores García-Cosío Carmena, José M. Sobrino-Márquez, Marta Farrero-Torres, José González-Costello, Manuel Martínez-Sellés, et al.


  • Update on heart transplantation: a consensus document

    by Davor Milicic, Ivo Planinc, Stamatis Adamopoulos, Tuvia Ben Gal, Marco Masetti, Steven Tsui, Bosko Skoric, Maja Cikes, Hrvoje Gasparovic, Eva Goncalvesova, et al.

    Heart transplantation (HT) remains the reference therapy for selected eligible patients with advanced heart failure (HF), recent developments in drug and device therapies notwithstanding. The majority of heart transplants are performed in Europe and the USA. However, the rate of heart transplants varies greatly among European countries, ranging from 10 per million population per annum. Due to donor organ shortage, durable mechanical circulatory support (MCS) became a practical solution for many advanced HF patients, either as a bridge to transplant or as destination therapy. The aim of the present consensus document is to provide a perspective on important issues regarding HT, in particular patient selection, pre-transplant work-up, matching of donor heart and recipient, strategies of bridging patients to transplant with temporary or durable MCS, as well as how to increase the donor organ pool. Furthermore, surgical techniques and complications are discussed, as well as immediate post-transplant, and long-term management including the main aspects of long-term follow up such as rejection surveillance, personalized immunosuppression and managing comorbidities. Cellular and antibody mediated rejection, early cardiac allograft failure, and indications for retransplantation are described. An emphasis is given on the most important post-HT complications, such as cardiac allograft vasculopathy, infections and malignancies. Finally, the need for tailored physical rehabilitation and psychosocial support, and impact of post-transplant status on reproductive health are discussed.


  • Person-Level Correlates of Nonadherence to Co-Medication in Spanish Heart Transplant Recipients

    by Maria Generosa Crespo-Leiro, Teresa Rosalía Pérez-Castro, Luis Almenar-Bonet, Carmen Segura-Saint-Gerons, Vicenç Brossa-Loidi, Javier Segovia-Cubero, Carmen Naya-Leira, Raquel López-Vilella, Amador López-Granados, Dolores Gil-Alonso, et al.

    Background: Nonadherence to heart transplantation-related medications involves both immunosuppressant drugs and co-medications; yet the correlates of heart transplantation patients’ overall medication nonadherence remain unclear. Objectives: We aimed to (1) describe nonadherence to both immunosuppressive and co-medication among Spanish heart transplantation patients, (2) to identify individual-level predictors of co-medication nonadherence, and (3) to describe nonadherence to non-pharmacological advice (eg, sun protection, physical activity, alcohol use) and clinical practice patterns of transplant centers. Methods: For this multicenter cross-sectional study, we surveyed 224 adult patients attending 5 Spanish centers 1 to 5 years post-transplantation. We assessed nonadherence to immunosuppressants and co-medications using the Basel Assessment of Adherence to Immunosuppressive Medication Scale (BAASIS © ). Correlates of nonadherence to co-medications were derived from the Integrative Model of Behavioral Prediction using self-report instruments, as were non-pharmacological treatment adherence and treatment centers’ practice patterns. Supported by causal mapping, multiple logistic regression analysis allowed adjustment for relevant confounders. Results: Nonadherence prevalence was 16.5% for co-medications (range across centers: 7.4%-25.0%), versus 9.4% (range: 2.6%-22.2%) for immunosuppressants. Adherence support varied across centers. Barriers to immunosuppressant nonadherence predicted co-medication nonadherence (odds ratio = 11.80; 95% CI, 2.59-53.69). Nonadherence to non-pharmacological treatments, particularly sunscreen use (59.3%) and physical activity (31.8%), were also common. Conclusions: Post-heart transplantation co-medication nonadherence surpasses immunosuppressant nonadherence. Barriers to immunosuppressant adherence strongly predict co-medication nonadherence. While no direct causal relationship is clear, immunosuppressant nonadherence may prove useful for identifying patients prone to co-medication nonadherence.

  • Top Cited Papers

    Natural History of Patients With Histologically Proven Acute Eosinophilic Myocarditis

    by Enrico Ammirati, Matteo Palazzini, Jukka Lehtonen, Luciano Potena, Mikko I. Mäyränpää, Johanna Rågback, Alberto Foà, Aitor Uribarri, Holger Thiele, María Vidal-Burdeus, et al.

    BACKGROUND: No large registries of patients with acute eosinophilic myocarditis (EM) are available. However, EM is perceived as a cardiac disease with high mortality, affecting mainly young and middle-aged adults according to small series and case reports. Awareness of the clinical presentation, associated systemic conditions, treatments, and outcomes of this uncommon condition is an unmet need. METHODS: In this international, multicenter, retrospective cohort study, 53 centers screened 193 patients with histologically proven acute EM between 1992 and 2023. After the exclusion of patients with insufficient data (n=10), symptoms lasting >30 days (n=19), or histological diagnosis not confirmed after review (n=8), 156 patients were included. RESULTS: Median age at presentation was 48 years (first to third quartile, 34–59 years) with male predominance (67.3%), and only 2 were pediatric cases (≤16 years of age; 1.3%). The main signs and symptoms at presentation were dyspnea (75.6%), fever (61.3%), and chest pain (53.2%). Unexpectedly, peripheral eosinophilia was reported in only 57.4% of cases, with a median cell count of 630 eosinophils/μL. The median left ventricular ejection fraction at presentation was 32% (first to third quartile, 25%–48%). The disorders most frequently associated with EM were eosinophilic granulomatosis with polyangiitis (22.4% of cases) and hypersensitivity forms (14.1%). Idiopathic/undefined forms accounted for 44.9% of cases, and miscellaneous causes accounted for 18.6%. In-hospital death or need for heart transplantation (HTx) occurred in 23 patients (14.7%; 22 deaths and 1 HTx), despite 43.6% being treated with temporary mechanical circulatory support and 92.9% being treated with immunosuppressive agents. Estimated rates of death or HTx at 1 and 3 years were 19.0% and 23.8%. Increased age, decreased left ventricular ejection fraction on admission, and no immunosuppressive therapy during hospitalization were independent predictors of death or HTx. A nonsignificant higher occurrence of deaths or HTx was observed in the hypersensitivity form (46.1%) compared with the eosinophilic granulomatosis with polyangiitis–associated form (13.1%) at 3 years ( P =0.15). CONCLUSIONS: Acute EM can often present without peripheral eosinophilia, and rates of in-hospital and midterm mortality or HTx are high. Endomyocardial biopsy is required to reach the final diagnosis of EM because relying on peripheral eosinophilia can lead to missing diagnosis. In-hospital immunosuppression is associated with HTx-free survival, although tailored immunosuppressive therapies are needed to improve outcomes. REGISTRATION: URL: https://www.clinicaltrials.gov ; Unique identifier: NCT06447935.